DIAMOND BIOFUND INC
Diamond Biofund Inc. is a venture capital firm specializing in evergreen funds. The firm seeks investment in start-ups and early ventures. It typically invests in biotechnology and medical investments, including new drug R&D, high-end medical equipment, innovative medical services and channels, and agricultural biotechnology. Diamond Biofund Inc. was founded in 2013 and is based in Taipei, Taiwan.
DIAMOND BIOFUND INC (6901) - Total Assets
Latest total assets as of September 2025: NT$9.39 Billion TWD
Based on the latest financial reports, DIAMOND BIOFUND INC (6901) holds total assets worth NT$9.39 Billion TWD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
DIAMOND BIOFUND INC - Total Assets Trend (2019–2024)
This chart illustrates how DIAMOND BIOFUND INC’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
DIAMOND BIOFUND INC - Asset Composition Analysis
Current Asset Composition (December 2024)
DIAMOND BIOFUND INC's total assets of NT$9.39 Billion consist of 48.2% current assets and 51.9% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 1.2% |
| Accounts Receivable | NT$0.00 | 0.0% |
| Inventory | NT$0.00 | 0.0% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how DIAMOND BIOFUND INC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: DIAMOND BIOFUND INC's current assets represent 48.2% of total assets in 2024, an increase from 41.3% in 2019.
- Cash Position: Cash and equivalents constituted 1.2% of total assets in 2024, down from 13.5% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
DIAMOND BIOFUND INC Competitors by Total Assets
Key competitors of DIAMOND BIOFUND INC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Bexil Cp
PINK:BXLC
|
USA | $29.44 Million |
|
Norte Grande
SN:NORTEGRAN
|
Chile | CL$2.91 Billion |
|
BlackRock Capital Allocation Trust
NYSE:BCAT
|
USA | $1.87 Billion |
|
Big Tech 50 R&D-Limited Partnership
TA:BIGT
|
Israel | ILA14.08 Million |
|
Zhuhai Huajin Capital Co Ltd
SHE:000532
|
China | CN¥2.38 Billion |
|
Shaanxi International Trust Co Ltd
SHE:000563
|
China | CN¥29.45 Billion |
|
Sichuan Shuangma Cement Co Ltd
SHE:000935
|
China | CN¥9.30 Billion |
|
Sk Securities
KO:001510
|
Korea | ₩7.28 Trillion |
DIAMOND BIOFUND INC - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - DIAMOND BIOFUND INC generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - DIAMOND BIOFUND INC is currently not profitable relative to its asset base.
DIAMOND BIOFUND INC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 46.23 | 69.93 | 74.56 |
| Quick Ratio | 46.23 | 69.93 | 74.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$4.20 Billion | NT$ 5.92 Billion | NT$ 10.60 Billion |
DIAMOND BIOFUND INC - Advanced Valuation Insights
This section examines the relationship between DIAMOND BIOFUND INC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.48 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -18.2% |
| Total Assets | NT$10.67 Billion |
| Market Capitalization | $103.34 Million USD |
Valuation Analysis
Below Book Valuation: The market values DIAMOND BIOFUND INC's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: DIAMOND BIOFUND INC's assets decreased by 18.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for DIAMOND BIOFUND INC (2019–2024)
The table below shows the annual total assets of DIAMOND BIOFUND INC from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$10.67 Billion | -18.15% |
| 2023-12-31 | NT$13.04 Billion | +16.50% |
| 2022-12-31 | NT$11.19 Billion | +5.38% |
| 2021-12-31 | NT$10.62 Billion | +14.47% |
| 2020-12-31 | NT$9.28 Billion | +201.37% |
| 2019-12-31 | NT$3.08 Billion | -- |